Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 394,487 | 288,622 | 279,273 | 249,717 | 179,413 |
| Cost of Goods | 32,158 | 20,500 | 27,105 | 26,130 | 35,699 |
| Gross Profit | 362,329 | 268,122 | 252,168 | 223,587 | 143,714 |
| Operating Expenses | 106,152 | 239,582 | 249,407 | 210,862 | 204,523 |
| Operating Income | 256,335 | 29,040 | 2,866 | 12,854 | -60,110 |
| Interest Expense | 16,479 | 78,715 | 70,978 | 78,204 | 37,482 |
| Other Income | 27,673 | -6,711 | 32,891 | -1,712 | 57,852 |
| Pre-tax Income | 267,529 | -56,386 | -35,221 | -67,062 | -39,740 |
| Income Tax | 26,885 | -792,965 | 7,690 | 4,228 | 4,368 |
| Net Income Continuous | 240,644 | 736,578 | -42,911 | -71,290 | -44,108 |
| Net Income | $240,644 | $736,578 | $-42,911 | $-71,290 | $-44,108 |
| EPS Basic Total Ops | 3.74 | 11.94 | -0.69 | -1.17 | -0.73 |
| EPS Basic Continuous Ops | 3.74 | 11.94 | -0.69 | -1.17 | -0.73 |
| EPS Diluted Total Ops | 3.29 | 11.41 | -0.49 | -1.17 | -0.93 |
| EPS Diluted Continuous Ops | 3.52 | 11.42 | -0.73 | -1.17 | -0.69 |
| EPS Diluted Before Non-Recurring Items | 3.29 | 0.32 | -0.64 | -1.17 | -0.93 |
| EBITDA(a) | $261,615 | $33,979 | $7,841 | $17,851 | $-54,848 |